Home/Stocks/Consumer Cyclicals

Entain PLC

ENT.L·Consumer Cyclicals·Market Cap £3.5b
Rank #71 of 100
Data from Excel Model · 100 Stocks Analysed
£5.33
-28.91% YTD
Target: £9.51(+78.3%)
52W: £5.00 - £10.31
Ad Space

Advertise with Strategyland

strategyland.uk

Score Analysis

Entain PLC is ranked #71 out of 100 UK stocks. Lower factor scores indicate better performance in that category.

Factor Breakdown

58/100
Average Score
Liquidity
Weak80/100
Valuation
Fair55/100
Profitability
Good32/100
Solvency
Weak70/100
Asset Efficiency
Excellent23/100
Mkt Trading
Weak62/100
Technical
Weak84/100

1. Valuation

Score: 55/100

Is ENT undervalued compared to its peers and fair value metrics?

3/5
valuation criteria met
FY26e P/E Ratio
9.0xRank 10/100
FY27e P/E Ratio
7.8xRank 9/100
Price-to-Book
5.51xRank 79/100
Price-to-Tangible Book
N/ARank 101/100
EV/EBITDA
7.8xRank 31/100

Key Valuation Metrics

Current P/E
N/A
Price-to-Earnings
FY26e P/E
9.0x
Forward estimate
FY27e P/E
7.8x
Forward estimate
P/B Ratio
5.51x
Price-to-Book
P/TBV
N/A
Price-to-Tangible Book
EV/EBITDA
7.8x
Enterprise Value
FY26e EV/EBITDA
6.5x
Forward estimate
FY27e EV/EBITDA
6.5x
Forward estimate

Analyst Consensus Target

Current Price
£5.33
Consensus Target
£9.51
Potential
+78.3%
Target
Bloomberg Median Target: £10.00

2. Profitability

Score: 32/100

How profitable is ENT relative to its peers?

2/6
profitability criteria met
TTM Profit Margin
-12.9%Rank 1/100
Current ROE
-54.7%
Current ROA
N/A
FY26e EPS
0.71Rank 36/100
TTM EPS
0.65
Net Income Growth
N/A
Profit Margin
-12.9%
ROE
-54.7%
FY27e ROE
42.7%
ROA
N/A

Earnings Per Share

3. Financial Health

Score: 70/100

How strong is ENT's balance sheet and financial position?

1/4
solvency criteria met
Debt-to-Equity
300.3%
Interest Coverage
N/A
Debt/EBITDA
Rank 21Rank 21/100
Altman Z-Score
0.74

Key Health Metrics

Quick Ratio
N/A
Below 1.0
Cash Ratio
0.52
Debt/Equity
300%
FCF Margin
0.3%

Altman Z-Score

0.74
Distress Zone
01.812.995+

4. Asset Efficiency

Score: 23/100

How efficiently does ENT deploy its assets and intellectual capital?

0/2
asset efficiency criteria met
Intangible/Asset
Intangible assets as a proportion of total assets — lower indicates more tangible, capital-efficient operations
N/A
R&D/Sales
Research & development spend relative to revenue — balanced R&D investment signals sustainable growth
N/A

Overall Asset Efficiency Rank

Rank within sector peers#23/100
Best (1)Worst (100)

What This Measures

Intangible/Asset — a lower ratio suggests the company's value is backed by tangible assets rather than goodwill or intangibles, reducing balance sheet risk.

R&D/Sales — captures the proportion of revenue reinvested into research and development, indicating innovation intensity and future growth investment.

4. Dividend

ENT pays a dividend yield of 2.49%.

Current Yield
2.49%
FY27e Yield
3.86%
FY26e DPS
0.098
FY27e DPS
N/A

Dividend Per Share Forecast

5. Technical Analysis

Score: 84/100

What do the technical indicators say about ENT?

1/4
technical criteria met
CMP vs 52W High
-48.3%Rank 96/100
CMP vs 52W Low
6.6%Rank 89/100
RSI 14 Day
50.6Rank 51/100
MA(50) > MA(200)
No (Bearish)Rank 29/100

RSI (14 Day)

50.6
Bullish
0 (Oversold)50100 (Overbought)

Moving Averages

MA 30-Day£5.60
MA 50-Day£5.61
MA 200-Day£7.11
SignalDeath Cross (Bearish)
MACD-10.49

Risk Metrics

Beta
N/A
3-Yr Std Dev
N/A
5-Yr Std Dev
N/A

6. Market Trading

Score: 62/100

How liquid and actively traded is ENT?

0/4
market trading criteria met
5D Avg Volume
8.4M
3M Avg Volume
3.5MRank 50/100
Volume Trend
139.7%
Beta
N/A
Shares Outstanding
639602618.0m
Free Float
N/A
Enterprise Value
$7364897.8b

Trading Volume

7. Peer Comparison

How does ENT compare to other Consumer Cyclicals stocks?

Overall Rank Comparison

Factor Score Comparison

StockRankLiquidityValuationProfitabilitySolvencyMkt TradingTechnical
ENT#71805532706284
JD.L#13114836150
BTRW.L#54547157496
KGF.L#115367788163
PSON.L#15116628328929
HWDN.L#1876133159491
PSN.L#2254401867880
Ad Space

Advertise with Strategyland

strategyland.uk

Note: The information provided is not intended as an offer or solicitation for the purchase or sale of any financial instruments but for investor relations purposes only. The aforementioned securities were offered to the public and currently trade on the secondary market at the exchange mentioned above. It is recommended that investors considering investing in any of these notes consult an approved MiFID Financial Advisor prior to investing.